Literature DB >> 18392407

Cervical dystonia: clinical and therapeutic features in 85 patients.

Carlos Henrique F Camargo1, Hélio A G Teive, Nilson Becker, Maria Helena Herdoíza Baran, Rosana Hermínia Scola, Lineu César Werneck.   

Abstract

We studied patients with cervical dystonia (CD) to determine clinical features and response to botulinum toxin A (BoNT/A). Patients were submitted to clinical, laboratory and neuroimaging evaluation. BoNT/A was injected locally in 81 patients using electromyographic guidance. Four patients who had had previous treatment were considered to be in remission. The average ages at onset of focal dystonia and segmental dystonia were greater than for generalized dystonia (p<0.0003). The severity of the abnormal head-neck movements were more severe among the patients with generalized dystonia (p<0.001). Pain in the cervical area was noted in 59 patients. It was not possible to determine the etiology of the disease in 62.3% of patients. Tardive dystonia was the most common secondary etiology. A major improvement in the motor symptoms of CD and pain was observed in patients following treatment with BoNT/A. The tardive dystonia subgroup did not respond to the treatment. Dysphagia was observed in 2.35% of the patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18392407     DOI: 10.1590/s0004-282x2008000100005

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  8 in total

1.  The occurrence of lateral shift in cervical dystonia.

Authors:  Marcello Esposito; Silvio Peluso; Raffaele Dubbioso; Roberto Allocca; Filippo Iorillo; Antonietta Coppola; Lucio Santoro
Journal:  Neurol Sci       Date:  2017-01-04       Impact factor: 3.307

2.  Long-Term Abobotulinumtoxin A Treatment of Cervical Dystonia.

Authors:  A R Bentivoglio; E Di Stasio; D Mulas; M L Cerbarano; T Ialongo; A Laurienzo; Martina Petracca
Journal:  Neurotox Res       Date:  2017-05-06       Impact factor: 3.911

Review 3.  Pain Relief in Cervical Dystonia with Botulinum Toxin Treatment.

Authors:  Carlos Henrique Ferreira Camargo; Lígia Cattai; Hélio Afonso Ghizoni Teive
Journal:  Toxins (Basel)       Date:  2015-06-23       Impact factor: 4.546

Review 4.  Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia.

Authors:  Wallace A Marsh; Deirdre M Monroe; Mitchell F Brin; Conor J Gallagher
Journal:  BMC Neurol       Date:  2014-04-27       Impact factor: 2.474

5.  Botulinum neurotoxin type A subtype 2 confers greater safety than subtype 1 in a rat Parkinson's disease model.

Authors:  Masanori Itakura; Tomoko Kohda; Takeya Kubo; Yuko Semi; Kazuhiro Nishiyama; Yasu-Taka Azuma; Hidemitsu Nakajima; Shunji Kozaki; Tadayoshi Takeuchi
Journal:  J Vet Med Sci       Date:  2014-05-21       Impact factor: 1.267

6.  Brief considerations on the dispensation profile of the botulinum toxin type A by the Brazilian Unified Health System for treatment of dystonias: Datasus data.

Authors:  Hsin Fen Chien; Ana Lucia Zuma de Rosso; André Sobierajski Dos Santos; Carlos Roberto de Mello Rieder; Debora Palma Maia; Delson José da Silva; Marcio da Cunha Andrade; Marcus Vinicius Della Coletta; Maria do Desterro Leiros da Costa; Nasser Allam; Roberto César Pereira do Prado; Vanderci Borges; Vitor Tumas; Wagner de Goes Horta
Journal:  eNeurologicalSci       Date:  2016-07-19

7.  Clinical Spectrum of Movement Disorders in Neurology Inpatients in a Tertiary Care Centre.

Authors:  Shabeer Ahmad Paul; Gouranga Prasad Mondal; Ramesh Bhattacharyya; Kartik Chandra Ghosh; Sarbajit Das; Suman Das; Hema Krishna; Chandrakanta Patra
Journal:  J Neurosci Rural Pract       Date:  2021-05-10

8.  Threshold of Clinical Severity of Cervical Dystonia for Positive (18)F-FDG PET/CT.

Authors:  Hyun Jung Lee; Young-Sil An; Young-Whan Ahn; Shin-Young Yim
Journal:  Ann Rehabil Med       Date:  2013-12-23
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.